Breast Cancer Response to Therapy: Can microRNAs Lead the Way?

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Breast cancer (BC) remains a significant cause of mortality in women, with advanced stages posing therapeutic challenges.
• Developing novel combinatorial treatments is crucial for enhancing BC therapy efficacy.
• MicroRNAs (miRNAs) are increasingly recognized as critical regulators of BC therapeutic resistance and susceptibility.

Purpose of the Study:

• To critically review the influence of miRNAs on BC response to various therapies.
• To explore the potential of miRNAs as a basis for novel therapeutic strategies in BC.
• To identify specific miRNAs that could enhance the efficacy of standard BC treatments.

Main Methods:

• Literature review of recent findings on miRNAs in BC therapy.
• Analysis of miRNA roles in radio-, chemo-, targeted, and hormone therapy resistance.
• Identification and evaluation of promising miRNA candidates for therapeutic intervention.

Main Results:

• Several miRNAs, including miR-21, miR-16, miR-205, miR-451, miR-182, and let-7 family miRNAs, show potential in modulating BC response to therapy.
• miR-21 inhibition is highlighted as a particularly promising strategy for improving invasive BC treatment.
• miRNA-based agents offer a potential adjunct to current standard treatment modalities.

Conclusions:

• miRNAs play a pivotal role in BC therapeutic outcomes.
• Targeting specific miRNAs, such as miR-21, could significantly improve the efficacy of existing breast cancer treatments.
• Future research and development of miRNA-based therapies alongside standard care hold promise for better BC patient management.